William H. Bradley, MD, discusses the 5-year follow-up of the SOLO-1 trial of olaparib maintenance in patients with BRCA1/2-mutated advanced ovarian cancer.
William H. Bradley, MD, a gynecologic oncologist at the Medical College of Wisconsin, discusses the 5-year follow-up of the SOLO-1 trial (NCT01844986) of olaparib (Lynparza) maintenance in patients with BRCA1/2-mutated advanced ovarian cancer.
One important observation from the SOLO-1 trial was its duration of treatment; patients received 300 mg of olaparib twice daily for up to 2 years or until disease progression, and physicians were allowed to continue treatment beyond 2 years.
According to Bradley, the study’s outcome establishes that this is a tolerable approach that could be used as standard of care with olaparib. While the treatment duration was longer than in the SOLO-2 trial (NCT01874353) and other trials of PARP inhibitors in the relapsed setting, the safety profile was similar. The rate of treatment discontinuation due to adverse events (AEs) in SOLO-1 was relatively low at 12%. Rare but dangerous AEs such as the development of acute myeloid leukemia did not occur at a higher rate than in other trials with a shorter treatment duration.
TRANSCRIPTION:
0:08 | One of the discussions that was held was the duration of therapy, and that's a really interesting point. On this trial, patients received the drug for 2 years. There were some patients, a subset [who] were allowed to continue if they had a measurable disease after that 2-year period and the physician that was treating them thought that that was in their benefit, but this is really a very small number.
0:27 | I actually think that the point about duration therapy off study, if you're going to use this as a standard of care, seems to be that 2-year window is actually a very reasonable one that the patient will receive a benefit. There's no reason to continue it past that unless there's something specific for that individual patient.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More